Watchlist Manager

Watchlist

Price: 43.14 CNY -1.06% Market Closed

Market Cap: ¥5.2B

	Nanjing Hicin Pharmaceutical Co Ltd SZSE:300584	CN
	Medigene AG XETRA:MDG1	DE

Income Statement

Currency: CNY

	Sep-2016	Dec-2016	Mar-2017	Jun-2017	Sep-2017	Dec-2017	Mar-2018	Jun-2018	Sep-2018	Dec-2018	Mar-2019	Jun-2019	Sep-2019	Dec-2019	Mar-2020	Jun-2020	Sep-2020	Dec-2020	Mar-2021	Jun-2021	Sep-2021	Dec-2021	Mar-2022	Jun-2022	Sep-2022	Dec-2022	Mar-2023	Jun-2023	Sep-2023	Dec-2023	Mar-2024	Jun-2024	Sep-2024	Dec-2024	Mar-2025	Jun-2025	Sep-2025
Revenue
Interest Expense	0	2	0	0	0	1	0	0	2	4	4	6	6	6	6	7	7	7	7	7	7	7	8	8	8	7	7	7	8	8	8	9	8	9	9	0	0
Revenue	262 N/A	281 +7%	305 +9%	333 +9%	388 +17%	455 +17%	543 +19%	624 +15%	679 +9%	712 +5%	759 +7%	826 +9%	871 +5%	925 +6%	880 -5%	845 -4%	788 -7%	706 -10%	702 -1%	647 -8%	612 -5%	578 -5%	567 -2%	529 -7%	504 -5%	526 +4%	493 -6%	520 +6%	525 +1%	518 -1%	505 -2%	493 -2%	500 +2%	504 +1%	542 +8%	576 +6%	615 +7%
Gross Profit
Cost of Revenue	(92)	(92)	(97)	(98)	(100)	(100)	(110)	(112)	(113)	(99)	(126)	(146)	(167)	(190)	(196)	(212)	(207)	(175)	(181)	(149)	(132)	(110)	(130)	(129)	(131)	(134)	(121)	(119)	(117)	(101)	(106)	(100)	(99)	(93)	(98)	(103)	(115)
Gross Profit	170 N/A	189 +11%	208 +10%	235 +13%	288 +23%	355 +23%	433 +22%	512 +18%	566 +11%	613 +8%	633 +3%	680 +7%	704 +4%	735 +4%	684 -7%	633 -7%	581 -8%	532 -8%	522 -2%	499 -4%	480 -4%	468 -2%	437 -7%	400 -8%	373 -7%	393 +5%	372 -5%	401 +8%	409 +2%	417 +2%	400 -4%	393 -2%	401 +2%	411 +3%	445 +8%	473 +6%	500 +6%
Operating Income
Operating Expenses	(114)	(135)	(152)	(173)	(219)	(283)	(346)	(426)	(473)	(514)	(529)	(565)	(585)	(616)	(569)	(532)	(494)	(463)	(458)	(449)	(437)	(437)	(405)	(369)	(347)	(356)	(335)	(366)	(372)	(369)	(351)	(337)	(344)	(361)	(394)	(420)	(448)
Selling, General & Administrative	(113)	(107)	(146)	(167)	(191)	(248)	(315)	(392)	(458)	(473)	(498)	(525)	(547)	(574)	(537)	(501)	(461)	(423)	(427)	(419)	(408)	(395)	(386)	(351)	(330)	(314)	(318)	(331)	(331)	(295)	(299)	(292)	(292)	(285)	(346)	(369)	(395)
Research & Development	0	(24)	0	0	0	(30)	0	0	(14)	(36)	(30)	(41)	(38)	(34)	(33)	(32)	(36)	(30)	(31)	(31)	(27)	(20)	(19)	(16)	(17)	(17)	(16)	(31)	(36)	(45)	(49)	(43)	(49)	(38)	(39)	(37)	(37)
Depreciation & Amortization	0	(4)	0	0	0	(6)	0	0	0	(6)	0	0	0	(10)	0	0	0	(14)	0	0	0	(24)	0	0	0	(28)	0	0	0	(33)	0	0	0	(37)	0	0	0
Other Operating Expenses	(1)	0	(5)	(6)	(29)	0	(31)	(34)	(1)	1	(0)	1	0	2	1	1	2	3	(0)	0	(2)	2	(1)	(1)	0	2	(1)	(4)	(5)	4	(2)	(1)	(3)	(1)	(9)	(14)	(17)
Operating Income	56 N/A	54 -3%	56 +4%	62 +11%	69 +10%	72 +5%	86 +20%	86 -1%	93 +9%	99 +6%	105 +6%	115 +10%	119 +4%	119 0%	115 -4%	102 -11%	86 -15%	69 -20%	64 -7%	49 -23%	43 -13%	32 -26%	31 -1%	31 +0%	26 -18%	36 +40%	37 +2%	35 -5%	36 +4%	47 +30%	49 +3%	56 +16%	57 +1%	51 -11%	51 +0%	54 +6%	52 -4%
Pre-Tax Income
Interest Income Expense	(2)	(2)	(1)	0	1	3	3	1	0	(2)	(3)	(4)	(5)	(5)	(6)	(6)	(7)	(6)	(7)	(6)	(6)	300	299	300	300	(5)	(5)	(6)	(6)	(7)	(8)	(9)	(9)	(9)	(9)	(9)	(10)
Non-Reccuring Items	0	0	0	0	0	2	0	3	3	(1)	(0)	(0)	(0)	0	0	(0)	(0)	(1)	0	0	0	(0)	(0)	(1)	(1)	(2)	(0)	0	0	(1)	0	(1)	(1)	(0)	0	1	1
Gain/Loss on Disposition of Assets	(0)	(0)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Other Income	2	1	0	(0)	0	(1)	(1)	(1)	(1)	(0)	(1)	(1)	(0)	(0)	(1)	(0)	(1)	(0)	(1)	(2)	(1)	(1)	(1)	(0)	(1)	(0)	(2)	(2)	(2)	(2)	(1)	(2)	(2)	(0)	(1)	(0)	3
Pre-Tax Income	56 N/A	53 -6%	55 +5%	62 +12%	69 +12%	76 +10%	88 +15%	90 +2%	96 +7%	96 +1%	101 +5%	110 +9%	115 +4%	114 0%	108 -5%	95 -12%	78 -17%	61 -22%	57 -8%	41 -27%	36 -14%	330 +830%	330 0%	330 +0%	324 -2%	29 -91%	29 0%	28 -4%	29 +5%	38 +30%	40 +7%	45 +11%	45 +0%	41 -9%	41 +0%	45 +9%	46 +2%
Net Income
Tax Provision	(8)	(7)	(8)	(9)	(9)	(11)	(13)	(13)	(14)	(13)	(13)	(15)	(16)	(17)	(16)	(14)	(11)	(7)	(6)	(2)	(1)	(46)	(46)	(48)	(47)	3	3	7	6	(1)	(3)	(3)	(3)	(1)	1	(1)	(1)
Income from Continuing Operations	48	45	48	53	60	66	75	77	82	83	89	95	98	97	92	81	68	55	51	39	34	285	284	282	277	32	32	34	35	36	37	42	42	40	42	44	44
Income to Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	1
Net Income (Common)	48 N/A	45 -6%	48 +6%	53 +11%	60 +12%	66 +10%	75 +14%	77 +3%	82 +7%	83 +1%	89 +6%	95 +8%	98 +3%	97 -1%	92 -5%	81 -12%	68 -16%	55 -19%	52 -7%	40 -23%	35 -12%	286 +714%	285 0%	282 -1%	278 -2%	32 -88%	32 -1%	34 +7%	35 +2%	36 +4%	37 +3%	42 +11%	42 +1%	40 -4%	42 +4%	45 +7%	45 +0%
EPS (Diluted)	0.54 N/A	0.5 -7%	0.43 -14%	0.44 +2%	0.49 +11%	0.56 +14%	0.62 +11%	0.64 +3%	0.68 +6%	0.69 +1%	0.74 +7%	0.79 +7%	0.82 +4%	0.81 -1%	0.76 -6%	0.67 -12%	0.56 -16%	0.46 -18%	0.43 -7%	0.33 -23%	0.29 -12%	2.38 +721%	2.37 0%	2.35 -1%	2.31 -2%	0.27 -88%	0.27 N/A	0.29 +7%	0.29 N/A	0.3 +3%	0.31 +3%	0.35 +13%	0.35 N/A	0.34 -3%	0.35 +3%	0.37 +6%	0.37 N/A

Income Statement Balance Sheet Cash Flow Statement

Nanjing Hicin Pharmaceutical Co Ltd
SZSE:300584

Income Statement

Earnings Waterfall
Nanjing Hicin Pharmaceutical Co Ltd

Income Statement
Nanjing Hicin Pharmaceutical Co Ltd

See Also

Company

Help

Tools

Stocks

Nanjing Hicin Pharmaceutical Co Ltd SZSE:300584

Income Statement

Earnings Waterfall Nanjing Hicin Pharmaceutical Co Ltd

Income Statement Nanjing Hicin Pharmaceutical Co Ltd

See Also

Company

Help

Tools

Stocks

Nanjing Hicin Pharmaceutical Co Ltd
SZSE:300584

Earnings Waterfall
Nanjing Hicin Pharmaceutical Co Ltd

Income Statement
Nanjing Hicin Pharmaceutical Co Ltd